Abstract. Epithelial-to-mesenchymal transition (EMT) endows cancer cells with enhanced invasive and metastatic potential during cancer progression. Fractalkine, also known as chemokine (C-X3-C motif) ligand 1 (CX3CL1), the only member recognized so far that belongs to the CX3C chemokine subfamily, was reported to participate in the molecular events that regulate cell adhesion, migration and survival of human prostate cancer cells. However, the relationship between CX3CL1 and EMT remains unknown. We treated DU145 and PC-3 cells with CX3CL1 under hypoxic conditions. The migration and invasion abilities of DU145 and PC-3 cells were detected by Transwell assays. Induction of EMT was verified by morphological changes in the DU145 and PC-3 cells and analysis of protein expression of EMT markers such as E-cadherin and vimentin. To identify the involved signaling pathway in CX3CL1-induced EMT, activation of epidermal growth factor receptor (EGFR) was measured using western blot analysis, and Slug expression was detected with or without an EGFR inhibitor prior to CX3CL1 treatment. Concentrations of soluble and total TGF-α in the CX3CL-treated DU145 cells were detected by ELISA. Additionally, we determined the involvement of the TACE/TGF-α/EGFR pathway in CX3CL1-induced EMT using RNA interference and specific inhibitors. CX3CL1 increased the migration and invasiveness of the DU145 and PC-3 cells, and resulted in characteristic alterations of EMT. Our results demonstrated that TACE/TGF-α/EGFR pathway activation and subsequent upregulation of Slug expression were responsible for CX3CL1-induced EMT, and contributed to the migration and inva sion of prostate cancer cells. Inhibition of TACE/TGF-α/EGFR signaling reversed EMT and led to reduced migration and invasion abilities of the prostate cancer cells. We provide initial evidence that CX3CL1 exposure resulted in EMT occurrence and enhancement of cell migration and invasion through a mechanism involving activation of TACE/TGF-α/EGFR signaling. These findings revealed that CX3CL1 may serve as a new target for the treatment of prostate cancer.
Introduction
In Western countries, prostate cancer has surpassed lung cancer as the most prevalent cancer and has become the second leading cause of cancer-related deaths among men (1) . Distant metastasis is the primary cause of death for the majority of prostate cancer patients. Early-stage prostate cancer depends upon androgens. However, 70-80% of patients with metastatic disease respond initially to androgen-deprivation therapy (ADT), yet the tumors may become hormone-refractory and lethal due to metastatic spread several years after initial treatment with anti-androgens (2) . Although microtubule-targeting agents, such as docetaxel, improve the overall survival of patients with distant disease by 2-3 months, tumor resistance eventually occurs (3) . In addition, several targeted therapies involved in clinical trials have shown little effect on prolonging survival. Therefore, new agents for the treatment of androgenresistant prostate cancer are needed.
Metastasis is a complex process whereby tumor cells penetrate the basement membranes of blood vessels, survive in the blood stream until extravasating to secondary sites, and form metastases (4) . This process requires epithelial-to-mesenchymal transition (EMT). During EMT, tumor cells lose epithelial polarity and adopt a spindle-shaped morphology and migratory fibroblastoid phenotype. These transitions endow cancer cells with enhanced invasive and metastatic potential (5) . EMT involves multiple signaling pathways, and is regulated by a set of transcription factors, including Snail, Slug and Twist, which lead to loss of cell-cell adhesion molecules such as E-cadherin and gain of mesenchymal proteins such as vimentin (6, 7) . Importantly, these transcription factors as key regulators of EMT have been confirmed to be critical to metastasis and the invasive ability of cancer cells in prostate cancer progression (8, 9) . Furthermore, loss of E-cadherin expression was found in high-grade prostate cancer and is associated with a reduction in survival (10, 11) . Therefore, clarifying the initial molecular mechanisms regulating the EMT phenotype allows the development of novel therapeutic strategies for the prevention and treatment of prostate cancer.
Recent findings have suggested that a wide variety of molecules promote EMT, such as chemokines (12) . Chemokines are small cytokine-like secreted proteins with selective chemoattractant properties and have emerged as important molecular regulators in cancer biology. Growing evidence has demonstrated that various chemokines promote tumor growth and metastasis via mediating EMT (13) . Fractalkine also known as chemokine (C-X3-C motif) ligand 1 (CX3CL1) is the only described member of the CX3C family. Recent studies have confirmed that CX3XL1 is highly expressed in various cancers, and is involved in tumor spread and organ-specific metastases (14) (15) (16) . In prostate cancer, the CX3CL1/CX3CR1 axis activates the PI3K/AKT survival pathway and plays a crucial role in skeletal metastasis (17) . Our previous study showed that hypoxia exposure upregulated CX3CR1 expression via HIF and the NF-κb pathway in androgen-independent prostate cancer cells (18) . Although there has been increasing interest in the role of CX3CL1/CX3CR1 during tumor metastasis, little is known concerning the detailed mechanisms involved.
Hypoxia, a well-recognized microenvironmental factor in prostate cancer development, is closely related with cancer relapse, metastases and resistance to chemotherapy (19) . Futhermore, hypoxia has been implicated in the promotion of the EMT process by activating a multitude of molecular signaling pathways that drive EMT (20) . The present study focused on whether CX3CL1/CX3CR regulate EMT and promote tumor migration and invasion in androgen-independent prostate cancer cells under hypoxic condition, and explored the potential molecular mechanisms involved.
Materials and methods
Reagents and antibodies. Recombinant human fractalkine (CX3CL1) and TGF-α were purchased from PeproTech (Rocky Hill, NJ, USA). EGFR inhibitor AG1478 was obtained from Cell Signaling Technology (beverly, MA, USA).
Primary antibodies against E-cadherin (cat. #3195), vimentin (cat. #5741) and slug (cat. #9585) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies for EGFR (cat.# sc-03), phosphor-EGFR (cat.# sc-101668, Tyr1173) and β-actin (cat.# sc-47778) were purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA). TGF-α neutralizing antibody (cat.# sc-9043) was from Calbiochem (La Jolla, CA, USA).
Cell culture and hypoxia treatment. Human prostate cancer cell lines DU145 and PC-3 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were cultrued in RPMI-1640 medium containing 10% fetal bovine serum (FbS; Gibco-bRL, Grand Island, NY, USA) and 1X penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) at 37˚C in a humidified atmosphere (5% CO 2 /95% air). For hypoxia treatment, the cells were incubated in a hypoxic chamber (Thermo Scientific) maintained at 1% O 2 , 5% CO 2 and 94% N 2 at 37˚C for 24-48 h.
Matrigel invasion and migration assays. The cell invasion assay was performed using Matrigel-coated 24-well Transwell inserts containing polycarbonate filters with 8-µm pores (BD biosciences) according to a previously published protocol. briefly, 5x10
4 cells in 200 µl of serum-free RPMI-1640 medium were seeded onto the upper chambers, whereas basal serum-free medium or medium with recombinant human CX3CL1 (200 ng/ml), TGF-α (50 µg/ml) or Ab-TGF-α (10 µg/ml) was added into the bottom chamber. After the assay chambers were incubated for 24 or 48 h under hypoxic conditions, the non-invading cells on the upper surface of the membrane were carefully removed with a cotton swab, and the filter membrane was fixed with cool methanol for 15 min, subsequently stained with 0.1% crystal violet for 30 min. Invading cells on the lower surface of the membrane were examined and counted under a microscope (Olympus IX51; Olympus, Japan) at a magnification of x200. Five random fields were numerically averaged and counted for each assay. Cell migration assay was performed with a similar procedure without Matrigel coating. All experiments were performed in triplicate and repeated three times.
ELISA assay. An equal number of cells were plated and cultured for the indicated times in RPMI-1640 medium supplemented with 10% FbS. The supernatant was collected and TGF-α levels were determined using a commercial human TGF-α ELISA kit (Oncogene, boston, MA, USA) according to the manufacturer's instructions.
Western blot analysis. Western blot analysis was carried out as described previously (18) . Briefly, cells were harvested, washed, and lysed in ice cold lysis buffer containing a mixture of protease inhibitors and phosphatase inhibitor. After centrifuged at 12,000 x g for 30 min, the supernatant was collected and the protein concentration in the extracts was determined using bCA reagent (beyotime Institute of biotechnology, Nanjing, China) according to the manufacturer's protocols. Equal amounts of proteins (40 µg) were loaded, fractionated by 12% SDS-PAGE and transferred onto nitrocellulose membranes. After being blocked with 5% non-fat milk in TbST for 2 h at room temperature, the membranes were incubated with primary antibodies for E-cadherin (1:1,000 rabbit monoclonal), vimentin (1:1,000 rabbit monoclonal), Slug (1:1,000 rabbit monoclonal) , EGFR (1:500 rabbit monoclonal), p-EGFR (1:300 rabbit monoclonal) and β-actin (1:1,000 rabbit monoclonal) at 4˚C overnight. The bound primary antibody was detected by incubating with appropriate horseradish peroxidase-conjugated secondary antibodies at a dilution of 1:2,000 in TbST for 2 h. The expression levels of β-actin were monitored as an internal control for the semi-quantitative PCR. Immunoreactive bands were visualized using the western blot analysis Super ECL Plus detection reagents (Applygen Technologies Inc., beijing, China) and analyzed by Quantity One software.
RNA interference. For the small interfering RNA (siRNA) treatment, oligonucleotides corresponding to nucleotide sequences of Slug and ADAM17 were synthesized commercially by Invitrogen (Life-Technologies). The siRNA sequences were as follows: Slug siRNA 1, 5'-AUGAGUUGUAACCAG GUCAGCUUCC-3'; Slug siRNA 2, 5'-AUACAUGACAUAU UUCCCUCCCUGG-3'; Slug siRNA 3, 5'-UUUCUUUGCU GUCAACACGAUUCUG-3'; and ADAM17 siRNA, 5'-CAGA AUCGUGUUGACAGCAAAGAAA-3'. Cells were transfected at 40-60% confluency with siRNA specific for Slug, ADAM17 or a scrambled sequence at the concentration of 100 nM using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's recommendations. The transfected cells were collected at 48 or 72 h and efficiency of protein knockdown was assessed by western blot analysis.
Statistical analysis. Each experiment was replicated in triplicate. All data are presented as mean ± SD. Statistical analyses were performed using Statistics Package for Social Science (SPSS 20.0 for Windows; IbM, Armonk, NY, USA). One-way ANOVA was used for multiple comparisons. A p-value <0.05 was considered statistically significant.
Results

CX3CL1 increases the migration and invasiveness of hypoxic
androgen-independent prostate cancer cells. Initially, we examined the effect of CX3CL1 on the abilities of invasion and migration in androgen-independent prostate cancer cells. Two types of androgen-independent prostate cancer cell lines DU145 and PC-3 were treated with CX3CL1 at various concentrations (0-400 ng/ml) for a period of 48 h under hypoxic conditions. Transwell assays showed that the ability of DU145 and PC-3 cells to cross the basement membrane matrix following treatment with CX3CL1 at a concentration of 200 or 300 ng/ml was markedly increased compared to the untreated cells. DU145 cells exhibited more aggressive and invasive activity than PC-3 cells responding to CX3CL1 stimulation (Fig. 1 ).
CX3CL1 induces a mesenchymal phenotype in hypoxic androgen-independent prostate cancer cells. EMT is a major process leading to increased migration and invasive abilities in cancer cells. To investigate whether the enhancement of migration and invasive abilities in androgen-independent prostate cancer cells resulted from the EMT process, we observed morphological changes of DU145 and PC-3 cells following treatment with CX3CL1 at various concentrations (0-300 ng/ml) for a period of 48 h under hypoxic conditions. As shown in Fig. 2A , most treated cells not only exhibited an fibroblastic and elongated morphology but also showed occasional misorientation and a loose association compared to the closely contacted monolayer, polygon cobblestone-like cells. An accompanying alteration in expression of epithelial and mesenchymal markers is often used to identify cells which are undergoing EMT. Western blot analysis showed that there was decreased expression of E-cadherin but elevated expression of vimentin in the DU145 and PC-3 cells upon CXCL3 stimulation at a concentration of 200 or 300 ng/ml for 48 h (Fig. 2b and C) . Taken together, we provided strong evidence that CXCL3 induced an EMT-like phenotype in the androgen-independent prostate cancer cells.
EGFR-dependent Slug pathway is implicated in CX3CL1-induced EMT.
Epidermal growth factor receptor (EGFR), an erbb-family receptor tyrosine kinase, is constitutively active in a variety of tumors and overexpressed in ~30% of prostate cancer cases (21) . Experimental and preclinical evidence showed that EGFR overexpression is correlated with prostate cancer aggressiveness (22) . Thus, to identify whether EGFR pathway activation exists in CX3CL-induced EMT occurrence, we determined the expression levels of total EGFR and phospho-EGFR (p-EGFR) in DU145 cells treated with 200 ng/ml of CX3CL1. Western blot analysis showed that p-EGFR expression was significantly elevated in the DU145 cells treated with CX3CL1 compared with the untreated cells ( Fig. 3A and C) , indicating CX3CL1-mediated activation of the EGFR signaling pathway. Accumulating evidence suggests that the EGFR family and its downstream mediators, for instance, Slug, serving as a transcription repressor of E-cadherin, are involved in EMT (23). Our results showed that CX3CL1 markedly elevated the protein expression level of Slug in the DU145 cells, and the EGFR inhibitor AG1478 abrogated this elevation ( Fig. 3b and D) , suggesting that CX3CL1 regulated Slug expression in an EGFR-dependent manner. Next, to further confirm the role of the EGFR-dependent Slug pathway in CX3CL-induced EMT, we examined the protein expression levels of EMT markers in the DU145 cells following CX3CL1 treatment alone or combined with AG1478 pretreatment. The western blot results demonstrated that CX3CL1 treatment led to a significant EMT change as indicated by E-cadherin and vimentin protein levels, whereas AG1478 pretreatment inhibited CX3CL1-induced downregulation of E-cadherin and upregulation of vimentin ( Fig. 4A and C) . In order to determine whether Slug is associated with the changes in the protein levels of E-cadherin and vimentin, DU145 cells were transfected with Slug-specific siRNA or non-specific siRNA, and western blotting was performed after 24 h of the transfections. As shown in Fig. 4b and D, Slug protein expression level was greatly reduced in the Slug-siRNA-transfected cells, compared with scrambled-siRNA transfected cells. Meanwhile, transfection with Slug-siRNA attenuated the regulatory effect of CX3CL1 on E-cadherin and vimentin protein expression, which indicated that Slug was involved in CX3CL-induced EMT. Taken together, we provided evidence that CX3CL caused EGFR pathway activation and subsequent Slug expression, which led to the EMT process.
TACE/TGF-α is responsible for CX3CL1-induced EGFR activation and EMT in hypoxic DU145 cells. EGFR is activated
by binding of its specific ligands. TGF-α is one of the key ligands for EGFR. Thus, we hypothesized that CX3CL1 may activate EGFR through increased shedding of pro-TGF-α. After CX3CL1 treatment for 20 min, the concentrations of soluble and total TGF-α in culture medium were detected by ELISA. Our results demonstrated that the concentration of soluble TGF-α significantly increased but that of total TGF-α remained unchanged upon CX3CL1 stimulation ( Fig. 5A and b) . To further investigate the role of TGF-α in CX3CL-induced EGFR activation, DU145 cells were pretreated with a neutralizing antibody of TGF-α (Ab-TGF-α) to inhibit TGF-α activity. The western blot analysis showed that CX3CL1-induced EGFR activation was significantly inhibited by Ab-TGF-α (Fig. 5C and D) , indicating that TGF-α activity is essential to CX3CL1-induced EGFR activation in DU145 cells. Tumor necrosis factor-α converting enzyme (TACE or ADAM17) has been found to be a metalloprotease that cleaves membrane-bound TGF-α, resulting in release of TGF-α ectodomains and transactivation of EGFR (24) . Our previous study reported that TACE/ADAM17 activity is essential for TGF-α maturation in prostate cancer cells. DU145 cells were transfected with specific siRNA for ADAM17 (verified in our previous studies) or Scrambled-siRNA, prior to treatment with CX3CL1. ELISA analysis revealed that the content of soluble TGF-α in culture supernatants was markedly decreased in the hypoxic DU145 cells pre-transfected with ADAM17-siRNA, but not Scrambled-siRNA (Fig. 5E and F) , which suggest that downregulation of ADAM17 attenuated CX3CL1-induced increase in TGF-α activity. These results indicate that ADAM17 is responsible for CX3CL1-induced TGF-α secretion.
To verify the role of TACE/TGF-α in CX3CL1-induced EGFR activation, DU145 cells were pre-transfected with ADAM17-siRNA or Scrambled-siRNA, followed by treatment with CX3CL1 for 24 h. Western blot analysis showed that CX3CL1-induced p-EGFR expression was inhibited by ADAM17-siRNA pre-transfection. Moreover, exogenous supplement of TGF-α compensated the inhibitory effect of ADAM17 downregulation (Fig. 5G and H) . Taken together, these data suggest that TACE/TGF-α was responsible for CX3CL1-induced EGFR activation in hypoxic DU145 cells.
Finally, we investigated the role of TACE/TGF-α in EMT marker protein expression regulated by CX3CL1. Western blot results showed that there was decreased expression of E-cadherin but elevated expression of vimentin in DU145 cells upon CX3CL1 stimulation compared with the control group, whereas either ADAM17-siRNA pre-transfection or Ab-TGF-α pretreatment abrogated the regulatory effect of CX3CL1 on EMT marker protein expression. In addition, exogenous supplement of TGF-α compensated the inhibitory effect of ADAM17 or TGF-α blockade on expression levels of EMT markers regulated by CX3CL1 (Fig. 6 ). These data demonstrated that the TACE/TGF-α signaling pathway was involved in CX3CL1-induced EMT of DU145 cells. 
CX3CL1-mediated TACE/TGF-α/EGFR signaling pathway contributes to migration and invasion of DU145 cells.
Firstly, to investigate the role of EGFR and Slug in the enhancement of migration and invasive abilities of DU145 cells induced by CX3CL1, Matrigel invasion and migration assays were carried out in DU145 cells after treatment with CX3CL1 alone or combined with pretreatment with AG1478 or Slug-siRNA transfection. As shown in Fig. 7 , CX3CL1 treatment markedly enhanced the abilities of DU145 cells to cross the basement membrane matrix. Moreover, inhibition of either EGFR or Slug significantly repressed the migration and invasive abilities of the CX3CL1-treated DU145 cells, indicating that the EGFR-dependent Slug pathway was involved in CX3CL1-induced migration and invasion of DU145 cells. Subsequently, we determined the role of TACE/TGF-α in cell migration and invasion induced by CX3CL1. Consistent with the alterations of EMT mentioned above, Matrigel invasion and migration assays demonstrated that CX3CL1 treatment alone increased cell migration and inva sion, whereas either ADAM17-siRNA pre-transfection or Ab-TGF-α pretreatment abrogated the regulatory effects of CX3CL1 on cell migration and invasion. Meanwhile, exogenous supplement of TGF-α compensated the inhibitory effect of ADAM17 downregulation (Fig. 8) . These results suggest that TACE/GF-α was essential for the regulatory effects of CX3CL1 on cell migration and invasion.
Discussion
Epithelial-to-mesenchymal transition (EMT), first described by developmental biologists, is a critical process during embryonic development and organogenesis (2) (3) (4) (5) (6) 8, 10, (12) (13) (14) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Recently, EMT is increasingly considered to play a vital role in tumor invasion and metastasis, and is closely correlated with tumor recurrence. Accumulating evidence indicates that EMT could drive many phenotypic and functional alterations that endow tumor cells with the ability to mobilize via a complex signaling pathway (26) . Therefore, regulation of EMT could be an effective strategy to control cancer progression. CX3CL1, the only member recognized so far that belongs to the CX3C chemokine subfamily, was reported to participate in the molecular events that regulate cell adhesion, migration and survival of human prostate cancer cells (27) . In addition, CX3CL1-CX3CR1 binding was also found to play a crucial role in prostate cancer progression and skeletal metastasis (17) . However, whether CX3CL1 exerts its function by initiating the EMT process in prostate cancer remains unknown. In the present study, we found that CX3CL1 induced migration and invasion of androgen-independent prostate cancer cells under hypoxic condition in vitro. We hypothesized that CX3CL1-induced migration and invasion of prostate cancer cells resulted from EMT initiation. Our results showed that under hypoxic conditions, notably morphological changes of DU145 and PC-3 cells were observed after CX3CL1 stimulation for 48 h. Most untreated cells exhibited classical round with tight junctions, and polygon cobblestone-like with typical epithelial cell morphology. However, upon CX3CL1 stimulation, most treated cells became spindle-like with loose connections instead of epithelial-like with tight connections, which morphologically indicated that CX3CL1 induced EMT in DU145 and PC-3 cells. Subsequently, we detected changes in the expression levels of EMT marker proteins in the DU145 and PC-3 cells to further verify whether these morphological changes resulted from functional alterations. Our results revealed that CX3CL1 reduced the expression of epithelial cell marker, E-cadherin, whereas expression of mesenchymal cell marker, vimentin, was significantly elevated. These results imply that CX3CL1 induced an EMT-like phenotype in androgen-independent prostate cancer cells.
EMT is a complicated pathological process, involving complex network regulation. A variety of molecules regulate EMT. The epidermal growth factor receptor (EGFR) family belongs to the tyrosine kinase receptor family, which is widely involved in many physiological or pathological processes such as cell proliferation and differentiation, embryonic development, apoptosis and metastasis (28, 29) . Our study provides initial evidence that CX3CL1 exposure resulted in EGFR transactivation and subsequent Slug expression, which led to the EMT process. G protein-coupled receptor (GPCR) is an important cell membrane receptor, which could be activated by a variety of extracellular physical and chemical stimuli, such as neurotransmitters, chemokines, hormones and drugs. These signals play vital roles in regulating cellular functions (30) . Currently, it is generally accepted that EGFRs act as an important conduit for multiple GPCR-related stimuli. Evidence suggests that the EGFR and GPCR pathways usually overlap and interact in cell growth and tissue remodeling (31) . CX3CR is the highly selectively chemokine receptor for CX3CL1, belonging to the GPCR family. Commonly, CX3CL1 exerts its functions though binding with its receptor CX3CR1. Thus, we speculated that CX3CL1/CX3CR1 binding activates EGFR and its downstream signaling pathway.
The matrix metalloprotease (MMP or ADAM) family are surface membrane-associated proteins responsible for the cleavage of several membrane proteins such as TGF-α, one of the ligands for the EGFR (32) . This biological cell process is called ectodomain shedding. TACE/ADAM17, one of the ADAM family members, is upregulated in several types of cancers and correlates with tumor aggressiveness. The crosstalk between TACE/ADAM17 and EGFR regulates cell proliferation, migration and invasion and survival (30) . In the present study, we evaluated the requirement for TACE-dependent EGFR ligand shedding for CX3CL-1 induced EGFR transactivation and EMT. Our results showed that CX3CL1 significantly increased the concentration of soluble TGF-α in culture medium, suggesting that CX3CL1 resulted in release of TGF-α ectodomains. In addition, inhibition of TGF-α or downregulation of ADAM17 depressed CX3CL1-induced EGFR transactivation. Our data demonstrated that TACE/TGF-α was responsible for CX3CL1-induced EGFR activation in hypoxic DU145 cells. Meanwhile, our results showed that the TACE/TGF-α signaling pathway was also responsible for CX3CL1-induced EMT-related gene expression, such as E-cadherin and vimentin. As expected, final Matrigel invasion and migration assays demonstrated that TACE/TGF-α were essential for the regulatory effects of CX3CL1 on cell migration and invasion.
In conclusion, CX3CL1/CX3CR1 induces EMT and migration and invasion of androgen-independent prostate cancer cells through TACE/TGF-α/EGFR pathway activation. These findings revealed that CX3CL1 may serve as a new target by which to treat prostate cancer.
